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MR Diagnosis of a Pulmonary Embolism:
Comparison of P792 and Gd-DOTA for
First-Pass Perfusion MRI and 
Contrast-Enhanced 3D MRA in 
a Rabbit Model
Objective: To compare P792 (gadomelitol, a rapid clearance blood pool MR
contrast agent) with gadolinium-tetraazacyclododecanetetraacetic acid (Gd-
DOTA), a standard extracellular agent, for their suitability to diagnose a pul-
monary embolism (PE) during a first-pass perfusion MRI and 3D contrast-
enhanced (CE) MR angiography (MRA).
Materials and Methods: A perfusion MRI or CE-MRA was performed in a rab-
bit PE model following the intravenous injection of a single dose of contrast agent.
The time course of the pulmonary vascular and parenchymal enhancement was
assessed by measuring the signal in the aorta, pulmonary artery, and lung
parenchyma as a function of time to determine whether there is a significant dif-
ference between the techniques. CE-MRA studies were evaluated by their ability
to depict the pulmonary vasculature and following defects between 3 seconds
and 15 minutes after a triple dose intravenous injection of the contrast agents.
Results: The P792 and Gd-DOTA were equivalent in their ability to demon-
strate PE as perfusion defects on first pass imaging. The signal from P792 was
significantly higher in vasculature than that from Gd-DOTA between the first and
the tenth minutes after injection.  The results suggest that a CE-MRA PE could be
reliably diagnosed up to 15 minutes after injection.
Conclusion: P792 is superior to Gd-DOTA for the MR diagnosis of PE.
ulmonary embolisms (PE) affect an estimated 600,000 patients annually
in the US alone (1, 2). Since treatment reduces the mortality by a factor
of 10 (3), timely diagnosis is mandatory. A number of tests have been
introduced to help diagnose a PE. Namely, the ventilation-perfusion (V/Q) scintigra-
phy, which, for the last two decades, has been the initial test of choice at most medical
centers worldwide and has been extensively evaluated (4). The diagnosis of a PE is
primarily based on the presence of a perfusion defect following a vascular territory in
the absence of a ventilation defect in that area. However, clearly concordant clinical
and scintigraphic findings are only present in a minority of patients and thus, either
empiric treatment or further imaging is required. More recently, the CT pulmonary
angiography (CTPA) has largely replaced V/Q-scanning as the first line imaging
modality for patients suspected of sustaining a PE. Unlike a scintigraphy which detects
perfusion defects, the CTPA detects a thrombus as a filling defect within the
pulmonary arterial branches. A contrast-enhanced (CE) pulmonary MR angiography
(MRA) has been shown in a number of small studies to allow the diagnosis of PE with
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Pan equivalent accuracy as the CPTA (5, 6). Although
preferable over CT for a number of reasons, particularly
due to the lack of ionizing radiation and potentially
nephrotoxic contrast agents, lack of availability, relatively
long acquisition times, and difficulty in monitoring patients
in the MR environment, it is not widely used. However,
recent technical advances, namely, the introduction of
parallel imaging techniques, have helped overcome many
of those obstacles (7, 8). In addition, it has recently been
shown that a time-resolved MRA technique employing
sensitivity encoding (SENSE) to assess both intravascular
filling defects and perfusion defects, has higher sensitivity
than the CTPA alone and was equivalent to a combined
strategy involving CTPA and V/Q scanning (9). A
shortcoming of all currently available MR contrast agents is
that they are extracellular and thus do not allow for the
acquisition of true perfusion maps (10, 11). More
importantly, their contrast kinetics only allow for very
short acquisition windows during the first pass, thus
limiting the maximum achievable spatial resolution and
accuracy that could theoretically be achieved.
Intravascular contrast agents have the potential to
improve the MR-based diagnosis of a PE because they
provide true perfusion images and prolong the imaging
window.
In this paper, we compare a rapid clearance blood pool
agent (RCBPA), P792, with a standard extracellular agent,
Gd-DOTA, based on its suitability for pulmonary MRA
and perfusion imaging in a rabbit model in which the left
pulmonary artery occlusion (PAO) is used as a model of
PE.
MATERIALS AND METHODS
Contrast Agents
Gd-DOTA (gadoterate acid, Dotarem
�, Guerbet-France)
is a nonspecific macrocyclic chelate which diffuses freely
into the interstitium (except for the brain), and is freely
excreted through the kidneys. The molecular weight of
Gd-DOTA is 0.56 kDa, while the relaxivity (R1) is 2.9 
L∙mmol
-1∙s
-1 at 1.5 Tesla (12). 
P792 (gadomelitol, Vistarem
�, Guerbet-France) is a
monodispersed monogadolinium macromolecule and a
tetrasubstituted derivative of Gd-DOTA. The structural
characterization of P792 has been described in detail in
past reports (12, 13). In summary, P792 is a RCBPA
characterized by the limited diffusion across normal
endothelium, while its clearance is equivalent to the
glomerular filtration rate. The molecular weight of P792 is
6.47 kDa, whereas the R1 is 29 L∙mmol
-1∙s
-1 at 1.5
Tesla.
The pharmacokinetic parameters of the two contrast
agents were previously determined in rabbits (13). The
volumes of the distribution were 187 ± 10 ml∙kg
-1 for
Gd-DOTA and 101 ± 10 ml∙kg
-1 for P792, respectively;
whereas, the total body clearances were 2.8 ± 0.2 ml∙
min
-1∙kg
-1 for both compounds. The ratios of the blood
concentration at 5 minutes divided by the theoretical initial
concentration were 19.3% ± 0.8 for Gd-DOTA and
41.7% ± 2.6 for P792, respectively (12). 
Animal Preparation
All experiments were performed with the approval of
the Institutional Animal Care and Use Committee.
A total of 17 experiments were performed in 13 New
Zealand white rabbits (weight 3-5 kg). The rabbits were
anesthetized with ketamine (60 mg∙kg
-1) and xylazine (6
mg∙kg
-1) (administered intramuscularly). Anesthesia was
maintained via intravenous sodium pentobarbital.
Temporary occlusion of the pulmonary artery was induced
in five of the rabbits using a non-detachable silicon balloon
(NDSB) filled with sterile saline. This animal model was
described in detail in a previous study (14). Briefly, a 5 Fr
sheath was placed in the surgically isolated right femoral
vein. Under fluoroscopic control, a 5 Fr angiographic
catheter (Cook, Bloomington, IN) was advanced over a
Terumo guide wire (0.038”, Terumo Corp., Tokyo, Japan)
into the inferior vena cava. Following the removal of the
guide wire, the NDSB (Occlusion Balloon Catheter with
Hieshima Taper, Boston Scientific Corp., Freemont, CA)
was advanced through this angiographic catheter as a guide
into the left pulmonary artery. Once the NDSB was
properly positioned, a test occlusion was created and an X-
ray pulmonary angiography performed. Iodinated contrast
agent (Omniscan 300, Nycomed, Princeton, NJ) was
injected through the guiding catheter using the digital
subtraction technique. Next, the balloon was deflated and
the rabbit was placed in the MR system. The advantage of
this model is that alternating occlusion and reperfusion of
the pulmonary artery could be achieved by inflating and
deflating the balloon, respectively. Multiple cycles of
occlusion and reperfusion could be accomplished without
removing the rabbit from the magnet. The NDSB catheter
and all other components, used in vivo, were tested to
ensure that their magnetic susceptibility was negligible
prior to their use, and that sterile water was used to inflate
the balloon. 
MR Imaging
All images were obtained on 1.5 Tesla scanners (Siemens
Magnetom Vision or Sonata, Siemens Medical Systems,
Malvern, PA). 
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A perfusion MRI was performed on six animals without
PAO (DOTA: n = 3; P792: n = 3), and five animals with
PAO (DOTA: n = 2, P792: n = 3). In two animals, an MRA
was performed. 
Scout images were acquired and used to select a
transverse slice. Five images (to reach steady state) were
acquired using an inversion recovery turbo fast low-angle
shot (turboFLASH) according to the following parameters:
TI 300 ms, TR 3.3 ms, TE 1.4 ms, flip angle 8� , field of
view (FOV) 250 mm × 250 mm, matrix size 128 × 128,
and 1 acquisition. The gains were set and kept constant for
each of the five images. The rabbit was then injected with
0.1 mmol∙kg
-1 Meglumine Gadoterate (n = 5) or 13 
μ mol∙kg
-1 P792 (n = 6) through the sheath of the femoral
vein in a bolus fashion, followed by 3 cc of saline as a
bolus chaser. Since the relaxivity of P792 is 8 to 10 times
higher than Gd-DOTA, the injected dose of P792 was
correspondingly decreased in order to administer the
agents with equivalent T1 efficacy. Images were obtained
at every second after injection for 30 seconds. Moreover,
images were also acquired once per minute for the first 10
minutes and every five minutes for the next 20 minutes,
for a total of 30 minutes. The signal was measured for the
aorta, pulmonary artery, and both lungs in the CE images,
and plotted as a function of time.
Contrast-Enhanced Magnetic Resonance Pulmonary
Angiography
Three animals had P792 MRA’s (one with a PE and two
without a PE), whereas three animals had Gd-DOTA MRA
(one with a PE and two without a PE). All the rabbits were
hand-injected with a triple dose of either P792 or Gd-
DOTA. In four of the animals, angiograms were acquired
at 3 seconds, 5 and 15 minutes using a 3D FLASH
sequence with the following parameters: TR 4.6 ms, TE 1.8
ms, flip angle 3。 , FOV 390 mm, matrix size 135 × 512, 60
mm slab with 46 partitions (voxel size 2.8 × 0.8 × 1.3
mm) on a Vision Scanner (scan duration = 20 seconds).
Two rabbits underwent an MRA on a Sonata system,
using an 8-channel high resolution knee array coil (MRI
Devices Corporation, Waukesha, WI) and a 3D FLASH
sequence with a TR of 4.54 ms, TE 1.6 ms, flip angle 30。 ,
FOV 200 mm, matrix 256 × 384 and a voxel size of 0.8
× 0.5 × 0.9 mm at a scan time of 7 seconds. Parallel
imaging (GeneRalized Autocalibrating Partially Parallel
Acquisitions (GRAPPA) (8), was used with an acceleration
factor of 3, thus resulting in a scan duration of 7 seconds.
One animal was injected with P792, while the other was
injected with Gd-DOTA. Angiograms were acquired for
both techniques at 3 seconds, 30 seconds, 1, 3, 5, 10, and
15 minutes.
Statistical Analysis
The signal intensities at the different time points were
plotted. Differences between the two contrast agents were
tested for significance using an unpaired t-test.
Enhancement curves were plotted for the first 20
seconds after the start of the injection and washout curves
for up to 30 minutes after injection. The decay contents
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Fig. 1. Gd-DOTA (0.1 mmol∙kg
-1 bw) (top row) and P792-enhanced (0.013 mmol∙kg
-1 bw) (bottom row) images of normal rabbit lungs
at time of peak contrast (A), and 1 minute (B), 5 minutes (C) and 10 minutes (D) after injection. 
AB C Dwere calculated for the washout curves by fitting the data
to y = Ae
-Rt + C, where R is the washout rate, and t is the
time in minutes.
RESULTS
Perfusion Imaging
Perfusion images were successfully obtained in all 11
experiments with both contrast agents. Typical CE
perfusion images of a rabbit without a PE obtained with
Gd-DOTA and P792 at the time of peak contrast and at 1,
5, and 10 minutes post-injection are shown in Figure 1.
The images have a comparable signal at the time of peak
contrast, but the P792 image has a higher signal at later
time points. The heart and vessels are more visible in the
P792 image at five minutes after the contrast injection than
in the Gd-DOTA image at one minute post-injection. The
initial rates of enhancement for both contrast agents are
similar. In addition, no significant difference was found
between the maximum signal obtained in either the aorta
(p = 0.25) or the pulmonary artery (p = 0.41) (t-test). 
Washout curves from 1 to 30 minutes post-injection are
shown in Figure 2. The signal is significantly higher in the
P792 images of the aorta and the pulmonary artery for the
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Fig. 2. Average washout curves for Gd-DOTA (diamonds) and P792 (squares) in aorta (A), pulmonary artery (B), right lung (C) and left
lung (D). (Dose: Gd-DOTA 0.1 mmol∙kg
-1 bw, P792 0.013 mmol∙kg
-1 bw.) Data points for left and right lungs were obtained in rabbits
without pulmonary artery occlusion.
CD
Table 2. Decay Constants for Washout Curves Shown in
Figure 3. 
Aorta Aorta Pulm. Art. Pulm. Art.
Gd-DOTA P792 Gd-DOTA P792
0.109 0.095 0.197 0.090
0.152 DNC 0.178 DNC
0.182 0.071 0.148 DNC
0.158 0.090 0.123 0.113
0.147 0.092 0.173 0.095
DNC 0.210
Average 0.150 0.087 0.164 0.127
Note.─ Data were fit to y = Ae
-Rt + C. DNC indicates that fitting algorithm 
did not converge.
Table 1. P Values for Difference in Signal Intensity between
Gd-DOTA and P792 Enhanced Images at Various
Time Points. 
Time (min) Aorta Pulmonary Artery Right Lung Left Lung
01 0.010 0.10 0.47 0.43
05 0.002 0.03 0.20 0.44
10 0.030 0.04 0.16 0.23
15 0.120 0.11 0.01 0.01
20 0.260 0.15 0.48 0.21
25 0.480 0.44 0.40 0.33
30 0.190 0.38 0.44 0.09
Note.─ Those considered significant (p ≤ 0.05) are shaded.data acquired between 1 and 15 minutes after injection,
however, this was not the case in the lung parenchyma (see
Table 1 for p values). There is a significant difference
between the Gd-DOTA and P792 images of lung
parenchyma at 15 minutes. By 30 minutes, the signal in
both images attained a stable low point, suggesting that a
decay curve can be fit to the series to determine a washout
rate. The data were fit to y = Ae
-Rt + C, where y is the
signal intensity, A is an amplitude constant, C is an offset
constant, R is the washout rate, and t is the time in
minutes. The R for P792 was 42% lower than that of Gd-
DOTA in the aorta and 23% lower in the pulmonary
artery (Table 2). 
In the subset of rabbits with occluded arteries (Gd-
DOTA, n = 2; P792, n = 3), the signal is higher for both
contrast agents in the perfused lung than in the unperfused
lung during the initial enhancement and washout phase,
although the effect was only significant for P792 because
of the small number of studies.
Both contrast-agents were successful at delineating
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Fig. 4. Gd-DOTA (top row) and P792-enhanced (bottom row) images of two different rabbits, acquired at 3 seconds (A), 30 seconds (B),
1 (C), 3 (D), 5 (E), 10 (F) and 15 minutes (G) after contrast injection. (Dose: Gd-DOTA 0.3 mmol∙kg
-1 bw, P792 0.039 mmol∙kg
-1 bw.)
All images are filmed at identical window settings.
AB C D E F G
Fig. 3. Gd-DOTA (top row) and P792-
enhanced (bottom row) perfusion
images of rabbit with obstructed
pulmonary artery at time of peak
contrast (A) and one minute (B) after
injection of contrast agent. Note that fill-
in of occluded lung occurs for both
agents at one minute, likely by systemic
collaterals. (Dose: Gd-DOTA 0.1
mmol∙kg
-1 bw, P792 0.013 mmol∙kg
-1
bw.)
A
Bperfusion defects caused by temporary balloon occlusion.
Gd-DOTA and P792 perfusion-weighted images of rabbit
lungs during occlusion are shown in Figure 3. Additionally,
both agents demonstrated a perfusion defect in the lower
left lung and, the defects became less conspicuous over
time because the agents reached the portions of the
occluded lung region, possibly via collateral circulation or
incomplete occlusion of the artery.
Contrast-Enhanced Pulmonary MR Angiography
All CE-MR pulmonary angiography (MRPA) studies
were technically successful; the MR angiograms acquired
on the high-performance system with parallel imaging at 3
seconds, 30 seconds, 1, 3, 5, 10 and 15 minutes post-
contrast injection are shown in Figure 4. The vessels are
highly visible in both images at peak contrast; however,
after one minute post-injection, the vessels in the P792
image has a stronger signal than those in the Gd-DOTA
image. The P792 angiogram is readily readable even at 15
minutes post-injection. The images on the pulmonary
arterial phase image (3 seconds delay) allowed for the
delineation of the patent and occluded pulmonary arteries
in all animals and with both contrast agents. The scans
obtained at 5 and 15 minutes post-injection allowed the
delineation of the occluded pulmonary artery on the P792
enhanced studies only (Fig. 5).
DISCUSSION
Contrast-enhanced MRA has potential for diagnosing
PEs, despite its current shortcomings. Gadolinium-
enhanced MR angiography is a technique sensitive to the
method of contrast injection, the nature of the contrast
agent (nonspecific or blood pool agent), and to the acquisi-
tion parameters. Two distinct phases were identified for
the MRA: the bolus phase and the post-bolus phase (15).
The bolus phase is mainly sensitive to the injection
parameters such as dose, rate of injection and volume of
injection. Hence, the use of a blood pool agent (BPA) did
not provide any advantage over a nonspecific agent.
However, differences were observed between BPA and
nonspecific agents during the post-bolus phase. Because of
their vascular compartmentalization, plasma BPA concen-
trations during the post-bolus phase were much greater
than those of the nonspecific agent (12, 13, 15, 16). 
Our study demonstrates that excellent perfusion maps
can be obtained with P792, and, at a quality comparable to
those obtained with extracellular agents (14). The graphs
in Figure 2 show that P792 washes out of the blood vessels
significantly less quickly than Gd-DOTA. A look at Figure
3 reveals that it is also clear that the contrast between
normal lung and occluded lung parenchyma is sufficient for
diagnostic purposes in both the Gd-DOTA image and the
P792 image only at peak contrast. However, at later time
points, the differences disappear, likely due to collateral
perfusion, which reduces the conspicuity of the defect.
While these are important findings, we believe that
perfusion imaging will likely not play a major role in the
future, as the presence of perfusion defects is not specific
to PEs. 
The gold standard for the diagnosis of PEs is the
demonstration of a filling defect in the pulmonary arteries.
Current standard CE-MRA techniques can demonstrate
these filling defects; however, the techniques are only
reliable during the bolus phase, which makes accurate
bolus timing absolutely critical. Even the most advanced
Keilholz et al.
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Fig. 5. P792-enhanced (0.013 mmol∙kg
-1 bw) images of rabbit during balloon occlusion of left pulmonary artery at time of first pass (A),
as well as 5 minutes (B) and 15 minutes (C) after injection. 
ABCscanners do not provide adequately short scan times for
the performance of breathhold exams in respiratorily
compromised patients if isotropic resolution is desired.
Typical scan times for MRPA’s with 512 matrices are 15-
20 seconds, with a slab thickness between 120-160 mm.
This is usually not thick enough to completely cover the
lung. In comparison, scan times on state-of-the-art 16
detector MDCT scanners are in the range of 5 seconds for
full lung coverage with isotropic resolution and much
faster on 64 detector systems (our own unpublished data).
Some investigators have overcome this obstacle by acquir-
ing two separate sagittal acquisitions rather than one
coronal acquisition, thus necessitating two separate
contrast injections, which is itself problematic because the
second acquisition suffers from an increase in background
signal resulting from the first injection (6). Others have
utilized real-time imaging approaches with true fast
imaging with steady-state precession (true FISP) sequences,
demonstrating increased robustness from respiratory
motion artifacts (17). 
The development of time-resolved imaging and parallel
imaging techniques has furthermore significantly improved
our ability to diagnose PEs with MRI (7, 9, 18). With high
acceleration factors, the studies can indeed be performed
in less than 10 seconds breathholds, although this is still
twice as long as on MDCT scanners. Also, the issues with
bolus timing still remain, possibly rendering a study
nondiagnostic. Nevertheless, it was recently shown by
Ohno and coworkers (9) that a combined time-resolved
perfusion-angiography study is as accurate in the detection
of PE as a strategy combining CTPA and V/Q scanning. 
The ability to acquire high-resolution images during the
equilibrium phase is a major advantage of intravascular
MR contrast agents for the diagnosis of PE. The prolonged
imaging window can be used in many ways. It could allow
for the acquisition of multiple overlapping high-resolution
data sets with short separate breathholds, or the acquisition
of high resolution images using navigator techniques at the
lung bases, where the majority of PEs occur. In cases
where the bolus was missed on first pass imaging, repeti-
tion of the scan is possible without penalty. The advantage
of such an approach has already been demonstrated for
MR coronary angiographies (19). The simultaneous
enhancement of pulmonary arteries and veins is not really
a diagnostic obstacle, since on 3D data sets, pulmonary
veins can be easily traced to the left atrium.
The ability to obtain high-resolution pulmonary
angiographic images not only during first-pass, but also
during the equilibrium phase of P792, has clearly been
demonstrated in our experiments. The results from our MR
angiography cohort suggest that a diagnostic MRPA can be
obtained up to 15 minutes after the dynamic perfusion
study using P792. This would allow to repeat sequences
affected by respiratory or bulk motion and allow to
employ both cardiac and respiratory gating.
In conclusion, we demonstrated that P792, a member of
the RCBPAs, has potential for the detection of PEs using
both a first-pass perfusion MRI as well as a CE-MRA in a
rabbit model. Similarly, a P792 perfusion MRI is as
effective as the first-pass perfusion MRI using Gd-DOTA, a
standard extra-cellular agent, for the demonstration of
perfusion defects caused by PAO. Further, at a steady-
state, it significantly prolongs the time over which diagnos-
tic high-resolution MR angiographic images can be
obtained. Thus, for utilizing optimized imaging sequences
with or without cardiac and/or respiratory gating, further
studies seem warranted to fully explore the potential of
this agent for the MR diagnosis of PE.
References
1. Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ,
Palevsky HI, et al. The clinical course of pulmonary embolism.
N Engl J Med 1992;326:1240-1245
2. Goldhaber SZ. Pulmonary embolism. N Engl J Med 1998;
339:93-104
3. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of
pulmonary embolism. A controlled trial. Lancet 1960;1:1309-
1312
4. The PIOPED Investigators. Value of the ventilation/perfusion
scan in acute pulmonary embolism: result of the Prospective
Investigation of Pulmonary Embolism Diagnosis (PIOPED).
JAMA 1990;263:2753-2759
5. Meaney JF, Weg JG, Chenevert TL, Stafford-Johnson D,
Hamilton BH, Prince MR. Diagnosis of pulmonary embolism
with magnetic resonance angiography. N Engl J Med
1997;336:1422-1427
6. Oudkerk M, van Beek EJ, Wielopolski P, van Ooijen PM,
Brouwers-Kyuper EM, Bongaerts AH, et al. Comparison of
contrast-enhanced magnetic resonance angiography and
conventional pulmonary angiography for the diagnosis of
pulmonary embolism: a prospective study. Lancet
2002;359:1643-1647
7. Pruessmann KP, Weiger M, Scheidegger MB, Boesiger P.
SENSE: sensitivity encoding for fast MRI. Magn Reson Med
1999;42:952-962
8. Griswold MA, Jakob PM, Heidemann RM, Nittka M, Jellus V,
Wang J, et al. Generalized autocalibrating partially parallel
acquisitions (GRAPPA). Magn Reson Med 2002;47:1202-1210
9. Ohno Y, Higashino T, Takenaka D, Sugimoto K, Yoshikawa T,
Kawai H, et al. MR angiography with sensitivity encoding
(SENSE) for suspected pulmonary embolism: comparison with
MDCT and ventilation-perfusion scintigraphy. AJR Am J
Roentgenol 2004;183:91-98
10. Hatabu H, Tadamura E, Levin DL, Chen Q, Li W, Kim D, et al.
Quantitative assessment of pulmonary perfusion with dynamic
contrast-enhanced MRI. Magn Reson Med 1999;42:1033-1038
11. Fink C, Ley S, Puderbach M, Plathow C, Bock M, Kauczor HU.
3D pulmonary perfusion MRI and MR angiography of
P792 versus Gd-DOPA for Pulmonary Embolism MRI Diagnosis in Rabbit Model
Korean J Radiol 10(5), Sep/Oct 2009 453pulmonary embolism in pigs after a single injection of a blood
pool MR contrast agent. Eur Radiol 2004;14:1291-1296
12. Port M, Corot C, Rousseaux O, Raynal I, Devoldere L, Idee JM,
et al. P792: a rapid clearance blood pool agent for magnetic
resonance imaging: preliminary results. MAGMA 2001;12:121-
127
13. Port M, Corot C, Raynal I, Idee JM, Dencausse A, Lancelot E, et
al. Physicochemical and biological evaluation of P792, a rapid
clearance blood pool agent for magnetic resonance imaging.
Invest Radiol 2001;36:445-454
14. Keilholz SD, Mai VM, Berr SS, Fujiwara N, Hagspiel KD.
Comparison of first-pass Gd-DOTA and FAIRER MR perfusion
imaging in a rabbit model of pulmonary embolism. J Magn
Reson Imaging 2002;16:168-171
15. Corot C, Violas X, Robert P, Port M. Pharmacokinetics of three
gadolinium chelates with different molecular sizes shortly after
intravenous injection in rabbits: relevance to MR angiography.
Invest Radiol 2000;35:213-218
16. Corot C, Violas X, Robert P, Gagneur G, Port M. Comparison
of different types of blood pool agents (P792, MS325, USPIO)
in a rabbit MR angiography-like protocol. Invest Radiol
2003;38:311-319
17. Kluge A, Muller C, Hansel J, Gerriets T, Bachmann G. Real-
time MR with TrueFISP for the detection of acute pulmonary
embolism: initial clinical experience. Eur Radiol 2004;14:709-
718
18. Goyen M, Laub G, Ladd ME, Debatin JF, Barkhausen J,
Truemmler KH, et al. Dynamic 3D MR angiography of the
pulmonary arteries in under four seconds. J Magn Reson
Imaging 2001;13:372-377
19. Dirksen MS, Lamb HJ, Kunz P, Robert P, Corot C, de Roos A.
Improved MR coronary angiography with use of a new rapid
clearance blood pool contrast agent in pigs. Radiology
2003;227:802-808
Keilholz et al.
454 Korean J Radiol 10(5), Sep/Oct 2009